# Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

> **NCT03886493** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 7 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT03886493
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-28
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low accrual due to COVID-19 pandemic.
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886493, "Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03886493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*